After years of delays, NICE backs Celgene’s Revlimid in first-line MM

After years of delays caused by wrangling over price, NICE has recommended regular NHS funding for Celgene’s Revlimid in combination with dexamethasone, as an option for certain adults with previously untreated multiple myeloma.